Approximately 47% of people diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) have an actionable biomarker and may benefit from targeted therapy. 

If your lung cancer is driven by a biomarker, there may be additional treatment options available to you:

- When people with lung cancer are not tested for actionable biomarkers, they may be missing out on the benefits of therapies that target the specific drivers of their cancer.
- Some people may not receive comprehensive biomarker testing due to concerns about cost. Comprehensive biomarker testing can be expensive depending on insurance coverage, and some people may not have the ability to pay for this type of testing even with financial assistance.

Through the Lilly Lung Cancer NGS Program, eligible people can receive comprehensive biomarker testing at no cost.

To qualify, you need to meet all of the following criteria:

- You have advanced or metastatic NSCLC.
- You currently live and receive treatment in the United States or a US territory (including Puerto Rico, Guam, and the Marshall Islands).
- You do not have a known molecular biomarker from a prior test.
- You have not had prior comprehensive biomarker testing.
- You have not previously been tested under this Program.

Talk to your doctor* and find out if you’re eligible for the Lilly Lung Cancer NGS Program—at no cost to you.

*For more information about this Program, have your doctor contact Tempus at 800-739-4137 Option 1, email support@tempus.com, or visit tempus.com/LillyLungProgram.
What is a biomarker?
• A biomarker is any molecule that can be measured in your tissue, blood, or other bodily fluids
• Biomarkers may reveal the specifics of a person’s cancer, as well as how well the body may respond to certain types of treatment
• There are 2 types of biomarkers commonly used to tailor treatment for NSCLC:
  — Driver alterations: changes in your DNA or RNA that can cause your cancer to grow
  — Immunotherapy biomarkers: biomarkers that can show how the cancer interacts with your immune system

Testing for these biomarkers can help determine whether certain types of targeted therapies or immunotherapies may work well to treat your cancer.

What is comprehensive biomarker testing?
• Comprehensive biomarker testing in NSCLC includes testing for all recommended actionable biomarkers based on clinical guidelines to help doctors understand more about a person’s specific type of cancer
  — Comprehensive biomarker testing can be performed using either a tissue biopsy or in some cases a blood test
  — After the tumor tissue or blood sample is collected, it is sent to a lab for testing
• Next-generation sequencing (NGS) is a method for identifying actionable biomarkers in a single test, and is the type of comprehensive biomarker testing performed in this Program

How do doctors use comprehensive biomarker testing results?
• Biomarkers identified through comprehensive biomarker testing can be used to determine the appropriate treatment approach for your NSCLC, including the prescription of currently approved therapies or participation in an active clinical trial

With the advancements in cancer treatments, it is important to speak with your doctor about testing for all actionable biomarkers.

This content was adapted with permission from LUNGevity Foundation.

You will not be billed for this test.

DNA=deoxyribonucleic acid; RNA=ribonucleic acid.